Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Byotrol Plc LSE:BYOT London Ordinary Share GB00B0999995 ORDS 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.075 1.19% 6.375 6.25 6.50 6.375 6.025 6.30 1,686,042 16:22:35
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 5.7 0.2 0.1 127.5 26

Byotrol Share Discussion Threads

Showing 9401 to 9425 of 9825 messages
Chat Pages: Latest  381  380  379  378  377  376  375  374  373  372  371  370  Older
DateSubjectAuthorDiscuss
14/5/2020
12:56
There hasn't been any increase in orders since their last TU, 3 weeks ago. I would have expected them to show continuing significant increases in sales going forward, especially for June, as it's only 2 weeks away!!. 3 weeks they stated - 24 Apr. "We entered the new financial year with a strong order book exceeding £2m and expect to generate record sales from products (i.e. excluding licenses, royalties and technical development deals) in the first quarter of the year." https://byotrolplc.com/wp-content/uploads/2020/04/2020-04-24-TU-FINAL-pdf.pdf They haven't changed that £2m orders - no mention of orders or significant increases for June - only 2 weeks from now!! "Sales in March and April 2020 each exceeded £1m and we are expecting to show similarly strong performance in May. Our order book at the end of April stood at over £2m. " https://byotrolplc.com/wp-content/uploads/2020/05/2020-05-13-TU-IRI-SCJ-FINALpdf.pdf Where's the significant increases in orders they mentioned 3 weeks ago??? I would have thought the expected orders for Q1 to have exceeded £3m by now. More Jam.
sikhthetech
14/5/2020
12:45
As the company puts in place licensing deals with "material minimum annual guaranteed payments" I wonder if it will consider a dividend before long?
1gw
14/5/2020
12:25
Cash has been declining for years... As of March 31st, 6 weeks ago they only had £1.7m cash, which missed Finncap's expectations of £2.6m. With only £1.7m cash, I wonder if they will have a placing soon. Cash: "Cash balances at 31 March were £1.7m." Expectation: £2.6m. Cash: fy2018 £3.85m fy2019 £2.8m H12020 £2.01m fy2020 £1.7m
sikhthetech
14/5/2020
12:15
Byotrol - It sounds a great way of the group extending its reach in the US without incurring material cost, although they could ultimately miss out on the bigger prize.... New comment... hxxps://www.investorschampion.com/channel/blog/coronavirus-impact-14-may-infection-prevention-is-booming-and-we-learn-a-ne
investorschampion
14/5/2020
11:08
An interesting question now is whether the byotrol24 licensees want to pursue the Target agreement - that would seem like an easy win for them once they have an efficient supply chain scaled up. And perhaps if Walmart was the other retailer (as evidenced by the byotrol24 product on their website) could the new licensees land them as well? At the AGM I seem to remember David Traynor saying that the second retailer was still interested but that it would want byotrol to put some marketing spend behind the product - something byotrol wasn't prepared to do at the time (risking precious cash resources) but the new licensees presumably would if they think the margin and/or exposure would be beneficial. hTtps://www.walmart.com/ip/Byotrol-Disinfectant-Cleaners-32oz-White/187615966
1gw
14/5/2020
10:42
Advanced Hygienics (identified as a "sister company" of Integrated Resources) distributes the (byotrol) red-cross (and Protect-8) hand sanitisers in the US. What chance they might look to put some financial resource behind that in parallel with the byotrol24 venture? hTtps://byotrolplc.com/american-red-cross-hand-sanitizer-powered-byotrol/ hTtps://www.redcross.org/store/first-aid-supplies
1gw
14/5/2020
09:42
The main negative at the moment is competition to secure enough base ingredients to make their end products. This could restrict sales and increase costs.Apart from that BYOT looks an attractive proposition especially with new royalty incomes.
nashwan123
14/5/2020
09:38
Whatever happened to all those long term deals following the Swine flu pandanmic.. A DECADE AGO, including deals in US. "The significant increase in sales is in part due to the concern regarding swine flu; however it can also be attributed to a greater appreciation of the qualities, efficacy and broad applications of Byotrol. " "We remain confident of the prospects for Byotrol " Distributors & Parners " Healthcare through our relationship with Synergy Health plc in Europe and through distributors in the US * Food and beverage, both through distributors and direct sales * Consumer products through our joint venture, Byotrol Consumer Products Ltd. " https://uk.advfn.com/stock-market/london/byotrol-BYOT/share-news/Interim-Results/40388101
sikhthetech
14/5/2020
09:38
My thoughts exactly 1gw,really pleased they have now given a bit more clarity and like you say more to come.
riddlerone
14/5/2020
09:33
The great thing about the longer-term deals is the visibility it gives, once they are up and running. The minimum guaranteed payments give a baseline of secure (subject to the financial health of the licensee) cashflow and if the licensee is successful then royalty payments should progressively build upon that. Moving from supply agreements to technology licensing should improve margin and free up resources for their organic sales efforts. And once they have done a number of these multi-year deals there should be fewer (confidentiality) concerns about releasing aggregated multi-year forecast information which would make life easier for finnCap and investors to build sensible cashflow models to facilitate valuation.
1gw
14/5/2020
09:28
From 2018/19 results Given the mix of Byotrol's activities, gross margin across the sales mix is not a particularly meaningful measure of performance and is better considered on a segmental basis where the gross margin in the Professional segment increased to 40% (2018: 20%), boosted by the acquisition of Medimark, and in Pet a slight decrease to 43% (2018: 47%). The increase in Consumer margin largely reflects the income from sale of patents and IP over 2018 and 2019, as discussed in the Chief Executive's report.
riddlerone
14/5/2020
09:08
rimau1 - your £10m-£12m is going to be underlying product sales isn't it, if current demand and current supply constraints persist for most of the year? What about licence revenue? If they do book several years worth of guaranteed payments (and as I say I am not sure they would but think under IFRS15 they might have to) on the Tristel Cache, SC Johnson and/or byotrol24 licence deals that could be another material amount, couldn't it? They wouldn't have the cashflow from the out-years but they might have the revenue in this year's accounts. And having done the US/byotrol24, the company is now looking to land other agreements, so there is potential for a number of other agreements to be concluded this year, and potentially all with minimum guaranteed payment terms. "The agreement with Integrated Resources and the new agreement with SC Johnson Professional Ltd are two such examples and we expect to complete more as the year continues."
1gw
14/5/2020
09:03
Finncap retain their 9p target - and that would imply £9m revenues, which given the current £1m/month run rate may well be nicely exceeded. Once the increased demand is modelled to continue, as is likely imo in this new world, then that 9p target may be raised further: "Although we do not have FY 2021 forecasts at present, given the challenges of modelling the duration of demand, we reiterate our 9p target price, at which level a c.4.0x EV/Sales multiple would imply revenues of c.£9m. Given the current outlook, the likely fundamental shift that we are seeing in disinfection and the financial firepower that the two licensees bring, this is not an unrealistic outlook."
rivaldo
14/5/2020
08:47
The revenue expectation of £9m is disappointing. Compare that to their expectation of £6m, which was before the outbreak. They failed to beat the £6m revenue expectation even though the original expectation was before Covid19 outbreak. An extra £3m revenue with the biggest virus threat in years!!
sikhthetech
14/5/2020
08:42
Peter, "Somebody is selling blocks of 100,000 every few minutes since the opening today." Pump and dump.. The 100k sells probably rotating the shares..
sikhthetech
14/5/2020
08:41
Yep, i actually think revenues will land between £10m and £12m depending on covid. Worst case trading at 2.5x revenues its a stonking buy with the US uncertainty removed. Tristel which i also hold is pretty fully valued until FDA approval comes through trading at 7.5x 2020 revenues. I don’t use PE for these stocks whilst they are in a high growth phase but this is all just my own methodology.
rimau1
14/5/2020
08:36
sickinthehead you are struggling mate another deal and you will have an aneurysm making a lot of people here and your wife very happy
wisecat2
14/5/2020
08:35
Finncap are happy with £9m of revenue this year being achievable
dan_the_epic
14/5/2020
08:35
Somebody is selling blocks of 100,000 every few minutes since the opening today. Lots of shares on the move and some odd pricing going on.
petersinthemarket
14/5/2020
08:25
The initial upfront fee of only $250k (£200k) probably suggests Royalty fees are expected to be low. I think it's too little too late in US.
sikhthetech
14/5/2020
08:15
1gw, yes, they will recognise the licensing fee upfront in this years financials.
rimau1
14/5/2020
08:10
The £1m sales per month is during the initial stage of the virus. They said they don't expect to maintain that level going forward. After all these months of seeking a US partner, they couldn't find a major one. The US partner was already known. How much was the agency fee? Probably more than the initial fee $250k they receive from the partnership.
sikhthetech
14/5/2020
08:06
Particularly nice in the US deal to see an actual "up-front" I thought. Very biotech.
1gw
14/5/2020
08:00
It's difficult to estimate what the US deal could be worth, but potentially I think it is huge. The key will be how much resource the new consortium puts behind the product, and of course what the royalty rate is. Originally, when byotrol started talking about looking for a partner, finnCap talked about needing $5m of marketing spend to get to $20m of sales, which was seen as a "breakout" level. Then there is the supply chain - how quickly can they put an efficient supply chain in place and what levels of production can they reach. It is a 10 year license, so if the consortium succeeds in capturing material market share then byotrol will have a valuable asset at the end of the 10 years. The US should also act as a shop window for other markets - we've already seen the Hong Kong distributor freight in byotrol24 to sell there. On this year's financials, as I read today's announcement they are moving away from supply agreements and towards straight licensing agreements. I hesitate to speculate on IFRS15 rules, but I think if it is a pure licensing agreement with no "performance obligations" beyond supplying the license then they may book any guaranteed payments (even if to be realised over several years) once the license has been signed - perhaps someone better-acquainted with IFRS interpretation can comment here? So potentially this year they have significant product sales (£12m run rate it seems) plus material license revenue. And the £1m/month product sales are presumably still supply-constrained, so there is potential to ramp up further as the supply chain constraints ease, although at some point the extraordinary current demand may reduce.
1gw
14/5/2020
08:00
Great news, the share price should continue to re-rate in the near term.
tonytyke
Chat Pages: Latest  381  380  379  378  377  376  375  374  373  372  371  370  Older
ADVFN Advertorial
Your Recent History
LSE
BYOT
Byotrol
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200705 11:50:05